FogPharma Secures $145M for Solid Tumor Treatment Development

FogPharma recently announced securing $145 million in a Series E funding round aimed at advancing its solid tumor treatment into clinical trials. Led by Nextech Invest, the funding saw participation from new investors such as RA Capital Management, Rock Springs Capital, General Catalyst, Samsara Biocapital, Marshall Wace, Catalio Capital Management, Symbiosis, Sixty Degree Capital, and former Johnson & Johnson CEO Alex Gorsky. Existing investors, including ARCH Venture Partners, Fidelity Management and Research Company, GV, Comorant Asset Management, and venBio Partners, also contributed.

Alexis Borisy has joined FogPharma’s board of directors. The company previously raised $178 million in a Series D round in 2022, which prepared the FOG-001 candidate for clinical entry. A prior funding round in March 2021 secured $107 million in Series C.

The newly acquired funds will support the clinical development of FOG-001, currently in a Phase I/II trial for solid tumors, and expand its pipeline, including potential treatments for acute myeloid leukemia. FOG-001 is designed to inhibit a critical oncogenic process in the Wnt/β-catenin signaling pathway, common in several cancers such as colorectal cancer.

CEO Mathai Mammen expressed optimism about the potential of FOG-001 to address key oncogenic signaling pathways, stating that the latest funding would advance the company’s clinical development and commercialization plans, as well as strengthen their discovery efforts against other disease targets.

FogPharma’s helicon platform integrates stabilized helical peptides with computational physics and AI to target previously undruggable cellular mechanisms.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!